CSL Limited
CSL
Rankning i aktier
#364
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aktiekurs
$138.43
Marknadsvärde
$66.43B
Förändring (1 dag)
-0.14%
Förändring (1 år)
-3.24%
Land
AU
Handel CSL Limited (CSL)
Kategori
Healthcare
Antal utestående aktier för CSL Limited (CSL)
Antal utestående aktier per June 2026: 478.91M
Enligt de senaste finansiella rapporterna och aktiekursen för CSL Limited är det aktuella antalet utestående aktier 478.91M. I slutet av June 2024 hade företaget 483.01M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för CSL Limited (CSL) från 2000 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 478.91M | -1.03% |
| 2025 | 483.88M | 0.18% |
| 2024 | 483.01M | 0.17% |
| 2023 | 482.17M | 2.86% |
| 2022 | 468.76M | 3.05% |
| 2021 | 454.87M | 0.23% |
| 2020 | 453.81M | 0.20% |
| 2019 | 452.92M | 0.13% |
| 2018 | 452.35M | -0.65% |
| 2017 | 455.33M | -1.44% |
| 2016 | 462.00M | -2.08% |
| 2015 | 471.82M | -2.48% |
| 2014 | 483.82M | -2.97% |
| 2013 | 498.61M | -3.97% |
| 2012 | 519.23M | -3.94% |
| 2011 | 540.53M | -4.63% |
| 2010 | 566.78M | -4.78% |
| 2009 | 595.24M | 8.21% |
| 2008 | 550.11M | 0.44% |
| 2007 | 547.71M | 0.30% |
| 2006 | 546.08M | -7.12% |
| 2005 | 587.97M | 10.00% |
| 2004 | 534.52M | 11.94% |
| 2003 | 477.51M | 0.53% |
| 2002 | 474.99M | 5.89% |
| 2001 | 448.57M | 12.11% |
| 2000 | 400.11M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | -46.98% |
US
|
|
| 396.00M | -17.31% |
US
|
|
| - | - |
CH
|
|
| 62.19M | -87.02% |
NL
|
|
| 0.00 | -100.00% |
BE
|
